New Potential Type 1 Diabetes Treatment Found in Mice Study

Scientists have discovered a possible treatment for type 1 diabetes through a recent study involving mice. Researchers from Stanford University School of Medicine found that by resetting the immune systems of diabetic mice and generating new insulin-producing cells, they could completely reverse the disease in all their test subjects, as per a press release from the university.

The study involved 19 prediabetic mice that were given a nontoxic “conditioning” treatment, which included low levels of radiation and a specific antibody designed to reduce certain immune cells known as T cells. The intention was to lower the immune response of these mice, thus allowing for more effective testing of new treatments.

Subsequently, the mice received stem cell transplants using bone marrow from other mice combined with donor islet cells, which are responsible for insulin production.

The researchers aimed to establish “mixed chimerism”—essentially creating a hybrid immune system with both the mice’s own cells and those of the donors. According to findings published in the Journal of Clinical Investigation, this approach prevented diabetes from developing in all 19 prediabetic mice.

Furthermore, the study looked at nine mice already diagnosed with long-term type 1 diabetes. Remarkably, all nine were cured after receiving treatments that combined stem cell therapy with islet transplantation.

The scientists observed no significant side effects or weakened immunity in the treated mice. They expressed optimism that, although the study was limited to animal testing and involved some level of radiation, the treatment could eventually be applicable to humans.

This “gentler preconditioning approach” might also pave the way for stem cell transplants to be a potential treatment for other autoimmune conditions, such as rheumatoid arthritis and lupus, along with non-cancerous blood disorders like sickle cell anemia.

Seung K. Kim, MD, PhD, a co-author of the study, remarked on the significance of creating animals with hybrid immune systems, a method already being utilized for other diseases in clinical settings. “We believe this approach could be transformative for people with type 1 diabetes and other autoimmune diseases,” he said.

Dr. Mark Siegel, a senior medical analyst, provided insights on these findings, cautioning that while the research is preliminary, it holds promise for human application. He emphasized that, to be truly effective, this methodology would require modifications tailored through genetic analysis and artificial intelligence. “It’s not a one-size-fits-all solution,” he noted.